WO1996020732A3 - Administration atraumatique de vehicules d'apport de genes - Google Patents

Administration atraumatique de vehicules d'apport de genes Download PDF

Info

Publication number
WO1996020732A3
WO1996020732A3 PCT/US1995/016967 US9516967W WO9620732A3 WO 1996020732 A3 WO1996020732 A3 WO 1996020732A3 US 9516967 W US9516967 W US 9516967W WO 9620732 A3 WO9620732 A3 WO 9620732A3
Authority
WO
WIPO (PCT)
Prior art keywords
administration
gene delivery
delivery vehicles
traumatic
gdvs
Prior art date
Application number
PCT/US1995/016967
Other languages
English (en)
Other versions
WO1996020732A9 (fr
WO1996020732A2 (fr
Inventor
Elizabeth S Song
Kieron J Kowal
Douglas J Jolly
Dominic Montisano
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Priority to EP95944671A priority Critical patent/EP0800403A2/fr
Priority to JP8521148A priority patent/JPH10512243A/ja
Priority to AU47431/96A priority patent/AU4743196A/en
Publication of WO1996020732A2 publication Critical patent/WO1996020732A2/fr
Publication of WO1996020732A9 publication Critical patent/WO1996020732A9/fr
Publication of WO1996020732A3 publication Critical patent/WO1996020732A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention se rapporte à l'administration atraumatique d'un ou plusieurs véhicules d'apport de gènes (GDV) à un animal. Une telle administration présente des avantages notables par rapport aux techniques antérieures d'administration dans la mesure où elle ne requiert pas d'injection ou d'intervention invasive sur le receveur, et entraîne ainsi beaucoup moins de risques de lésions. En outre, comme aucune injection ou intervention invasive n'est requise, ce procédé d'administration ne requiert pas les services d'un personnel hautement qualifié, peut se pratiquer dans des conditions moins stériles et entraîne un risque moins élevé d'infections, de lésions et d'autres effets secondaires.
PCT/US1995/016967 1994-12-30 1995-12-20 Administration atraumatique de vehicules d'apport de genes WO1996020732A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95944671A EP0800403A2 (fr) 1994-12-30 1995-12-20 Administration atraumatique de vehicules d'apport de genes
JP8521148A JPH10512243A (ja) 1994-12-30 1995-12-20 遺伝子送達ビヒクルの非外傷性投与
AU47431/96A AU4743196A (en) 1994-12-30 1995-12-20 Non-traumatic administration of gene delivery vehicles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36678894A 1994-12-30 1994-12-30
US08/366,788 1994-12-30

Publications (3)

Publication Number Publication Date
WO1996020732A2 WO1996020732A2 (fr) 1996-07-11
WO1996020732A9 WO1996020732A9 (fr) 1996-09-12
WO1996020732A3 true WO1996020732A3 (fr) 1996-12-12

Family

ID=23444505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016967 WO1996020732A2 (fr) 1994-12-30 1995-12-20 Administration atraumatique de vehicules d'apport de genes

Country Status (4)

Country Link
EP (1) EP0800403A2 (fr)
JP (1) JPH10512243A (fr)
AU (1) AU4743196A (fr)
WO (1) WO1996020732A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
ZA973642B (en) 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
US5945100A (en) * 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
WO1998008539A1 (fr) * 1996-08-26 1998-03-05 Chiron Corporation Therapie de vaccination apres l'infection par le virus de l'immunodeficience humaine (vih)
CA2266656A1 (fr) * 1996-09-17 1998-03-26 Chiron Corporation Compositions et procedes de traitement de maladies intracellulaires
US6096303A (en) * 1997-07-31 2000-08-01 Medical College Of Georgia Research Institute, Inc. Method to enhance treatment of cystic tumors
AU1029099A (en) * 1997-10-10 1999-05-03 Aventis Pharma Deutschland Gmbh Transfection system for the transfer of nucleic acids into cells
EP0908521A1 (fr) * 1997-10-10 1999-04-14 Hoechst Marion Roussel Deutschland GmbH Système de transfection pour le transfert d'ADN dans des cellules
EP0967288A1 (fr) * 1998-06-16 1999-12-29 Hoechst Marion Roussel Deutschland GmbH Système pour la transfection génique de celules
CA2315256A1 (fr) * 1997-12-16 1999-06-24 Valentis, Inc. Injection sans aiguille de molecules d'acide nucleique formules
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
DE10010959A1 (de) 2000-03-06 2001-09-20 Eppendorf Geraetebau Netheler Verfahren zum Übertragen von Material in einem Zellsystem
WO2002063026A1 (fr) * 2001-02-08 2002-08-15 Geneporter, Inc. Complexes et composants de ces derniers permettant l'introduction de polynucleotides dans des cellules eukaryotes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003769A1 (fr) * 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Transfert induit par adenovirus de genes vers la voie gastro-intestinale
EP0586076A2 (fr) * 1992-08-07 1994-03-09 American Home Products Corporation Vaccins adénoviraux recombinant
WO1994023582A1 (fr) * 1993-04-08 1994-10-27 Genetic Therapy, Inc. Vecteurs adenoviraux renfermant l'adn codant une proteine surfactant des poumons

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003769A1 (fr) * 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Transfert induit par adenovirus de genes vers la voie gastro-intestinale
EP0586076A2 (fr) * 1992-08-07 1994-03-09 American Home Products Corporation Vaccins adénoviraux recombinant
WO1994023582A1 (fr) * 1993-04-08 1994-10-27 Genetic Therapy, Inc. Vecteurs adenoviraux renfermant l'adn codant une proteine surfactant des poumons

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins

Also Published As

Publication number Publication date
JPH10512243A (ja) 1998-11-24
WO1996020732A2 (fr) 1996-07-11
AU4743196A (en) 1996-07-24
EP0800403A2 (fr) 1997-10-15

Similar Documents

Publication Publication Date Title
WO1996020732A3 (fr) Administration atraumatique de vehicules d'apport de genes
EP1238677A3 (fr) Emulsions grasses parentérales, comprenant de l'EDTA comme conservateur
AU693073B2 (en) Systems and methods for communicating with ambulatory medical devices such as drug delivery devices
AU4370593A (en) Tissue-specific implantable therapeutic agent delivery system
DE69535349D1 (de) Implantierbare aktive medizinische Vorrichtung mit Mittel zur Unterscheidung zwischen Ruhe- bzw. Aktivzustand des Patienten
AU8933391A (en) Medical drug formulation and delivery system
AU608264B2 (en) Delivery vehicles with amphiphile-associated active ingredient
EP0587379A3 (fr) Connecteur bipolaire coaxial pour dispositif médical implantable.
AU8046691A (en) Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
DE69333607D1 (de) Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen
DE59510531D1 (de) Behältnis zur Lagerung und Verabreichung von Injektions-, Infusions- und Diagnostikpräparaten
ATE361093T1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
AU3127697A (en) Intravenous catheter and delivery system
WO1994001147A3 (fr) Administration de medicaments a la volaille
BR9707637A (pt) Sistema implantável implante destinado a administração subcutânea ou local e conjunto farmacêutico
FR08C0001I2 (fr)
NZ234802A (en) Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
AU5673399A (en) Compositions and methods for treating intracellular infections
IL107153A (en) Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture
ITVI920062A1 (it) Assieme filtro, particolarmente per linee d'infusione e trasfusione medicale
DE69935526D1 (de) Supramolekulare komplexe enthaltende arzneimittel
AU5745494A (en) Pre-filled, sterilized syringe and method of making
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
AU5643299A (en) Humic acid and its use in the treatment of various conditions
EP0373388A3 (fr) Dérivés de pénème et procédé de préparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/18-11/18 AND 14/18-18/18,DRAWINGS,REPLACED BY NEW PAGES 1/19-11/19 AND 14/19-19/19;PAGES 12/18 AND 13/18,RENUMBERED AS PAGES 12/19 AND 13/19;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1995944671

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995944671

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995944671

Country of ref document: EP